HCV Vaccines
EASL 2016: Vaccines for HIV and Hepatitis C Could Potentially Be Administered Together
- Details
- Category: Experimental HCV Drugs
- Published on Friday, 22 April 2016 00:00
- Written by EASL
Immunization against HIV and hepatitis C virus (HCV) could potentially be combined without compromising immune response to either, though effective vaccines for both diseases are still elusive, according to research presented at the European Association for the Study of the Liver's International Liver Congress (EASL 2016) last week in Barcelona.
Hepatitis C Vaccine Is Safe and Induces Immune Responses in Early Human Trial
- Details
- Category: HCV Vaccines
- Published on Friday, 07 November 2014 00:00
- Written by University of Oxford
A new hepatitis C vaccine demonstrated good safely and tolerability in a first-in-humans Phase 1 clinical trial, with only mild and transient side effects, according to a report in the November 5 edition of Science Translational Medicine. The vaccine, which mimics immune responses in people who naturally clear hepatitis C virus (HCV) infection, led to increased production of T-cells targeting the virus. Phase 2 studies are now underway in Baltimore and San Francisco, with results expected in 2016.
EASL 2012: Having Only Wild-type Hepatitis B Virus Predicts Response to Interferon
- Details
- Category: HBV Treatment
- Published on Friday, 04 May 2012 00:00
- Written by Liz Highleyman
Chronic hepatitis B patients who do not have 2 common HBV mutations are more likely to achieve undetectable viral load and HBsAg loss when treated with pegylated interferon, according to study findings presented at the 47th International Liver Congress (EASL 2012) last month in Barcelona.
EASL 2012: Telbivudine Effective for Hepatitis B Patients Selected with Roadmap
- Details
- Category: HBV Treatment
- Published on Tuesday, 08 May 2012 00:00
- Written by Liz Highleyman
Telbivudine (Tyzeka) is an effective treatment for chronic hepatitis B with minimal emergence of drug resistance when using the "Roadmap" algorithm for selecting appropriate patients and deciding when to add other agents, according to a trio of studies presented at the 47th International Liver Congress (EASL 2012) last month in Barcelona.
Scientists Find Antibodies that Neutralize Multiple Strains of Hepatitis C Virus
- Details
- Category: HCV Vaccines
- Published on Tuesday, 10 April 2012 00:00
- Written by Press Release
As described in a report published in the April 4, 2012, online edition of Proceedings of the National Academy of Sciences, Erick Giang and Mansun Law from the Scripps Research Institute and colleagues have identified a set of antibodies with activity against 5 different antigenic regions on the E1E2 complex of the hepatitis C virus (HCV) outer envelope.
More Articles...
- Canadian Researchers Make Progress in Quest for Hepatitis C Vaccine
- Experimental Hepatitis C Vaccine Triggers T-Cell Responses in Early Clinical Trial
- AASLD 2011: Recombinant Hepatitis C Vaccine TG404 Shows Promise in Phase 2 Trial
- Discovery May Aid Development of Hepatitis C Vaccine
- Experimental HCV Vaccine Induces Broadly Neutralizing Antibodies in Mice and Monkeys
- New Phase 2b Study of Experimental Hepatitis C Vaccine ChronVac-C
- Researchers Report Promising Results from Studies of 3 Therapeutic HCV Vaccines
Web Design and Development by